Xenon Pharmaceuticals announced successful Phase 1 trial results for its pain treatment candidates XEN1701 and XEN1120, showing good safety and effective target engagement. Both drugs demonstrated strong potential as non-opioid pain therapies, with XEN1701 achieving high receptor occupancy without cardiovascular side effects and XEN1120 showing analgesic activity in preclinical models. Encouraged by these findings, Xenon plans to start Phase 2 proof-of-concept studies for acute pain in the first half of 2027. This progress highlights promising new options for acute and chronic pain management beyond opioids.
Xenon Pharmaceuticals' pain treatment candidates are progressing with positive Phase 1 results and plans for Phase 2 studies. For readers following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 19:12 WIB: out of 150 priced US health stocks, 91 rose and 53 fell. Notable movers include Incyte Corporation (INCY) at USD 112.32 with a 3.89% decline and 100% buy order activity, Amgen, Inc. (AMGN) at USD 468.69 up 3.73% with 82% buy orders, and Baxter International Inc (BAX) at USD 26.40 up 3.69%.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
